|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5208036A
(en)
|
1985-01-07 |
1993-05-04 |
Syntex (U.S.A.) Inc. |
N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4666829A
(en)
|
1985-05-15 |
1987-05-19 |
University Of California |
Polypeptide marker for Alzheimer's disease and its use for diagnosis
|
|
US5618920A
(en)
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
|
US4713366A
(en)
|
1985-12-04 |
1987-12-15 |
The Ohio State University Research Foundation |
Antigenic modification of polypeptides
|
|
US5096706A
(en)
|
1986-03-25 |
1992-03-17 |
National Research Development Corporation |
Antigen-based treatment for adiposity
|
|
US6548640B1
(en)
*
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
US5225539A
(en)
*
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US5278049A
(en)
|
1986-06-03 |
1994-01-11 |
Incyte Pharmaceuticals, Inc. |
Recombinant molecule encoding human protease nexin
|
|
US5231170A
(en)
|
1986-08-27 |
1993-07-27 |
Paul Averback |
Antibodies to dense microspheres
|
|
US5187153A
(en)
|
1986-11-17 |
1993-02-16 |
Scios Nova Inc. |
Methods of treatment using Alzheimer's amyloid polypeptide derivatives
|
|
US5220013A
(en)
|
1986-11-17 |
1993-06-15 |
Scios Nova Inc. |
DNA sequence useful for the detection of Alzheimer's disease
|
|
US4879213A
(en)
|
1986-12-05 |
1989-11-07 |
Scripps Clinic And Research Foundation |
Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
|
|
US4912206A
(en)
|
1987-02-26 |
1990-03-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
CDNA clone encoding brain amyloid of alzheimer's disease
|
|
WO1988007089A1
(en)
*
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
US5245015A
(en)
*
|
1991-04-26 |
1993-09-14 |
Tanox Biosystems, Inc. |
Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
|
|
US5583112A
(en)
|
1987-05-29 |
1996-12-10 |
Cambridge Biotech Corporation |
Saponin-antigen conjugates and the use thereof
|
|
US5571500A
(en)
|
1987-06-24 |
1996-11-05 |
Autoimmune, Inc. |
Treatment of autoimmune diseases through administration by inhalation of autoantigens
|
|
DE3856566T2
(de)
|
1987-06-24 |
2004-06-24 |
Brigham And Women's Hospital, Boston |
Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen
|
|
US5571499A
(en)
|
1987-06-24 |
1996-11-05 |
Autoimmune, Inc. |
Treatment of autoimmune diseases by aerosol administration of autoantigens
|
|
US5645820A
(en)
|
1987-06-24 |
1997-07-08 |
Autoimmune, Inc. |
Treatment of autoimmune diseases by aerosol administration of autoantigens
|
|
US5849298A
(en)
|
1987-06-24 |
1998-12-15 |
Autoimmune Inc. |
Treatment of multiple sclerosis by oral administration of bovine myelin
|
|
US5641474A
(en)
|
1987-06-24 |
1997-06-24 |
Autoimmune, Inc. |
Prevention of autoimmune diseases by aerosol administration of autoantigens
|
|
US5869054A
(en)
|
1987-06-24 |
1999-02-09 |
Autoimmune Inc. |
Treatment of multiple sclerosis by oral administration of autoantigens
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5231000A
(en)
|
1987-10-08 |
1993-07-27 |
The Mclean Hospital |
Antibodies to A4 amyloid peptide
|
|
CA1339014C
(en)
|
1987-10-08 |
1997-03-25 |
Ronald E. Majocha |
Antibodies to a4 amyloid peptide
|
|
JP2518911B2
(ja)
|
1987-10-23 |
1996-07-31 |
森永乳業株式会社 |
ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
|
|
US5089603A
(en)
*
|
1989-06-21 |
1992-02-18 |
Tanox Biosystems, Inc. |
Antigenic epitopes present on membrane-bound but not secreted iga
|
|
AU3056289A
(en)
|
1988-01-13 |
1989-08-11 |
Mclean Hospital Corporation, The |
Genetic constructs containing the alzheimer brain amyloid gene
|
|
US4912094B1
(en)
|
1988-06-29 |
1994-02-15 |
Ribi Immunochem Research Inc. |
Modified lipopolysaccharides and process of preparation
|
|
US5576184A
(en)
|
1988-09-06 |
1996-11-19 |
Xoma Corporation |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5227159A
(en)
|
1989-01-31 |
1993-07-13 |
Miller Richard A |
Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
|
|
US5262332A
(en)
|
1989-04-05 |
1993-11-16 |
Brigham And Women's Hospital |
Diagnostic method for Alzheimer's disease: examination of non-neural tissue
|
|
AU5439790A
(en)
|
1989-04-14 |
1990-11-16 |
Research Foundation For Mental Hygiene, Inc. |
Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
|
|
AU5525090A
(en)
|
1989-04-14 |
1990-11-16 |
Research Foundation For Mental Hygiene, Inc. |
Monoclonal antibody to amyloid peptide
|
|
WO1991001059A1
(de)
*
|
1989-07-10 |
1991-01-24 |
Siemens Aktiengesellschaft |
Leiterwicklungsanordnung für eine elektrische grossmaschine
|
|
KR0185747B1
(ko)
|
1989-12-20 |
1999-05-01 |
마리아 아이. 마마리노스 |
자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법
|
|
US5859205A
(en)
*
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
AU651097B2
(en)
|
1990-03-02 |
1994-07-14 |
Autoimmune, Inc. |
Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
|
|
CA2079880A1
(en)
|
1990-04-24 |
1991-10-25 |
William E. Van Nostrand |
Purification, detection and methods of use of protease nexin-2
|
|
US5753624A
(en)
|
1990-04-27 |
1998-05-19 |
Milkhaus Laboratory, Inc. |
Materials and methods for treatment of plaquing disease
|
|
ATE153534T1
(de)
|
1990-04-27 |
1997-06-15 |
John Mcmichael |
Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
|
|
GB9009548D0
(en)
|
1990-04-27 |
1990-06-20 |
Celltech Ltd |
Chimeric antibody and method
|
|
WO1991019810A1
(en)
|
1990-06-15 |
1991-12-26 |
California Biotechnology Inc. |
Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
|
|
US5780587A
(en)
|
1990-08-24 |
1998-07-14 |
President And Fellows Of Harvard College |
Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
|
|
US5702906A
(en)
|
1990-09-25 |
1997-12-30 |
Genentech, Inc. |
Antibodies to neurotrophic factor-4 (NT-4)
|
|
JPH06502071A
(ja)
|
1990-09-28 |
1994-03-10 |
ジ・アップジョン・カンパニー |
アルツハイマーのアミロイド前駆遺伝子を有するトランスジェニック動物
|
|
EP0553291B1
(en)
|
1990-10-15 |
2006-03-08 |
Autoimmune, Inc. |
Treatment of autoimmune diseases by oral administration of autoantigens
|
|
WO1992013069A1
(en)
|
1991-01-21 |
1992-08-06 |
Imperial College Of Science, Technology & Medicine |
Test and model for alzheimer's disease
|
|
US5192753A
(en)
|
1991-04-23 |
1993-03-09 |
Mcgeer Patrick L |
Anti-rheumatoid arthritic drugs in the treatment of dementia
|
|
WO1992022653A1
(en)
|
1991-06-14 |
1992-12-23 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5672805A
(en)
|
1991-07-18 |
1997-09-30 |
The Regents Of The University Of California |
Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
|
|
US5434050A
(en)
|
1991-08-13 |
1995-07-18 |
Regents Of The University Of Minnesota |
Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
|
|
US5837268A
(en)
|
1991-10-16 |
1998-11-17 |
University Of Saskatchewan |
GnRH-leukotoxin chimeras
|
|
JPH07506720A
(ja)
|
1992-01-07 |
1995-07-27 |
アテナ ニューロサイエンシーズ， インコーポレイテッド |
アルツハイマー病のトランスジェニック動物モデル
|
|
US5679348A
(en)
|
1992-02-03 |
1997-10-21 |
Cedars-Sinai Medical Center |
Immunotherapy for recurrent HSV infections
|
|
NZ249704A
(en)
|
1992-02-11 |
1996-11-26 |
Jackson H M Found Military Med |
A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
|
|
DE69332518T2
(de)
|
1992-02-28 |
2003-09-04 |
Autoimmune Inc |
Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
|
|
US5714350A
(en)
*
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5604102A
(en)
|
1992-04-15 |
1997-02-18 |
Athena Neurosciences, Inc. |
Methods of screening for β-amyloid peptide production inhibitors
|
|
US5441870A
(en)
|
1992-04-15 |
1995-08-15 |
Athena Neurosciences, Inc. |
Methods for monitoring cellular processing of β-amyloid precursor protein
|
|
US5851787A
(en)
|
1992-04-20 |
1998-12-22 |
The General Hospital Corporation |
Nucleic acid encoding amyloid precursor-like protein and uses thereof
|
|
AU4116793A
(en)
|
1992-04-24 |
1993-11-29 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
GB9209118D0
(en)
|
1992-04-28 |
1992-06-10 |
Sb 120 Amsterdam Bv |
Vaccine compositions
|
|
WO1993025210A1
(en)
*
|
1992-06-18 |
1993-12-23 |
President And Fellows Of Harvard College |
Diphtheria toxin vaccines
|
|
ES2143716T3
(es)
|
1992-06-25 |
2000-05-16 |
Smithkline Beecham Biolog |
Composicion de vacuna que contiene adyuvantes.
|
|
US5766846A
(en)
|
1992-07-10 |
1998-06-16 |
Athena Neurosciences |
Methods of screening for compounds which inhibit soluble β-amyloid peptide production
|
|
US5837672A
(en)
|
1992-07-10 |
1998-11-17 |
Athena Neurosciences, Inc. |
Methods and compositions for the detection of soluble β-amyloid peptide
|
|
US6610493B1
(en)
*
|
1993-06-17 |
2003-08-26 |
Brigham And Women's Hospital |
Screening compounds for the ability to alter the production of amyloid-β peptide
|
|
WO1994001772A1
(en)
|
1992-07-13 |
1994-01-20 |
The Children's Medical Center Corporation |
SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
|
|
KR950702635A
(ko)
|
1992-07-31 |
1995-07-29 |
크리스틴 헬렌 수덴 |
감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria)
|
|
AU667578B2
(en)
|
1992-08-27 |
1996-03-28 |
Deakin Research Limited |
Retro-, inverso-, and retro-inverso synthetic peptide analogues
|
|
US5958883A
(en)
|
1992-09-23 |
1999-09-28 |
Board Of Regents Of The University Of Washington Office Of Technology |
Animal models of human amyloidoses
|
|
AU5358494A
(en)
|
1992-10-13 |
1994-05-09 |
Duke University |
Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein
|
|
DE69334337D1
(de)
|
1992-10-26 |
2010-08-26 |
Elan Pharm Inc |
Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP)
|
|
US5605811A
(en)
|
1992-10-26 |
1997-02-25 |
Athena Neurosciences, Inc. |
Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
|
|
US6210671B1
(en)
*
|
1992-12-01 |
2001-04-03 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with L-selectin
|
|
US5750349A
(en)
|
1993-01-25 |
1998-05-12 |
Takeda Chemical Industries Ltd. |
Antibodies to β-amyloids or their derivatives and use thereof
|
|
US5955317A
(en)
|
1993-01-25 |
1999-09-21 |
Takeda Chemical Industries, Ltd. |
Antibodies to β-amyloids or their derivatives and use thereof
|
|
US5358708A
(en)
|
1993-01-29 |
1994-10-25 |
Schering Corporation |
Stabilization of protein formulations
|
|
DE614989T1
(de)
|
1993-02-17 |
1995-09-28 |
Morphosys Proteinoptimierung |
Verfahren für in vivo Selektion von Ligandenbindende Proteine.
|
|
CA2158455C
(en)
*
|
1993-03-17 |
2003-05-27 |
Nicholas P. Restifo |
Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
|
|
SG48309A1
(en)
|
1993-03-23 |
1998-04-17 |
Smithkline Beecham Biolog |
Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
|
|
IT1270939B
(it)
|
1993-05-11 |
1997-05-26 |
Angeletti P Ist Richerche Bio |
Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
|
|
WO1994028412A1
(en)
|
1993-05-28 |
1994-12-08 |
The Miriam Hospital |
Composition and method for in vivo imaging of amyloid deposits
|
|
US5464823A
(en)
|
1993-07-20 |
1995-11-07 |
The Regents Of The University Of California |
Mammalian antibiotic peptides
|
|
CA2168459C
(en)
|
1993-07-30 |
2002-10-01 |
Mohammed Anjam Khan |
Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein
|
|
WO1995005393A2
(en)
|
1993-08-18 |
1995-02-23 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Lipopolysaccharide-binding and neutralizing peptides
|
|
JPH09501936A
(ja)
|
1993-08-26 |
1997-02-25 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
|
|
AU707083B2
(en)
|
1993-08-26 |
1999-07-01 |
Bavarian Nordic Inc. |
Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
|
|
WO1995006407A1
(en)
|
1993-08-30 |
1995-03-09 |
The Regents Of The University Of California |
Novel component of amyloid in alzheimer's disease and methods for use of same
|
|
NZ274338A
(en)
*
|
1993-09-07 |
1998-02-26 |
Smithkline Beecham Corp |
Chimeric and humanised il-4 monoclonal antibodies and their use
|
|
US5652334A
(en)
|
1993-09-08 |
1997-07-29 |
City Of Hope |
Method for design of substances that enhance memory and improve the quality of life
|
|
US5385887A
(en)
*
|
1993-09-10 |
1995-01-31 |
Genetics Institute, Inc. |
Formulations for delivery of osteogenic proteins
|
|
DE69435171D1
(de)
|
1993-09-14 |
2009-01-08 |
Pharmexa Inc |
Pan dr-bindeproteinen zur erhöhung der immunantwort
|
|
US5470951A
(en)
|
1993-09-29 |
1995-11-28 |
City Of Hope |
Peptides for antagonizing the effects of amyloid βprotein
|
|
US5858981A
(en)
*
|
1993-09-30 |
1999-01-12 |
University Of Pennsylvania |
Method of inhibiting phagocytosis
|
|
CA2174501A1
(en)
|
1993-10-20 |
1995-04-27 |
Warren J. Strittmatter |
Method of binding material to the .beta.-amyloid peptide
|
|
CA2172507C
(en)
|
1993-10-22 |
2008-12-02 |
Jeffrey L. Cleland |
Methods and compositions for microencapsulation of antigens for use as vaccines
|
|
US5744368A
(en)
|
1993-11-04 |
1998-04-28 |
Research Foundation Of State University Of New York |
Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
US5434170A
(en)
|
1993-12-23 |
1995-07-18 |
Andrulis Pharmaceuticals Corp. |
Method for treating neurocognitive disorders
|
|
CA2182311A1
(en)
|
1994-01-27 |
1995-08-03 |
Karen Hsiao |
Transgenic non-human mammals with progressive neurologic disease
|
|
US5877399A
(en)
|
1994-01-27 |
1999-03-02 |
Johns Hopkins University |
Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
|
|
JPH09511492A
(ja)
|
1994-02-03 |
1997-11-18 |
ザ ピコワー インスティテュート フォア メディカル リサーチ |
アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
|
|
AUPM411994A0
(en)
|
1994-02-25 |
1994-03-24 |
Deakin Research Limited |
Epitopes
|
|
US5795954A
(en)
|
1994-03-04 |
1998-08-18 |
Genentech, Inc. |
Factor VIIa inhibitors from Kunitz domain proteins
|
|
US6270757B1
(en)
*
|
1994-04-21 |
2001-08-07 |
Genetics Institute, Inc. |
Formulations for IL-11
|
|
US6372716B1
(en)
*
|
1994-04-26 |
2002-04-16 |
Genetics Institute, Inc. |
Formulations for factor IX
|
|
AU686818B2
(en)
|
1994-05-25 |
1998-02-12 |
John Mcmichael |
Materials and methods for treatment of plaquing diseases
|
|
US5622701A
(en)
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
|
US6417178B1
(en)
|
1994-07-19 |
2002-07-09 |
University Of Pittsburgh |
Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
|
|
US6114133A
(en)
|
1994-11-14 |
2000-09-05 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
|
|
US5589154A
(en)
|
1994-11-22 |
1996-12-31 |
Rutgers, The State University Of New Jersey |
Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
|
|
US5688651A
(en)
|
1994-12-16 |
1997-11-18 |
Ramot University Authority For Applied Research And Development Ltd. |
Prevention of protein aggregation
|
|
JP2000510813A
(ja)
*
|
1995-02-06 |
2000-08-22 |
ジェネテイックス・インスティテュート・インコーポレイテッド |
Ｉｌ−１２用処方
|
|
US5786180A
(en)
|
1995-02-14 |
1998-07-28 |
Bayer Corporation |
Monoclonal antibody 369.2B specific for β A4 peptide
|
|
US5624937A
(en)
*
|
1995-03-02 |
1997-04-29 |
Eli Lilly And Company |
Chemical compounds as inhibitors of amyloid beta protein production
|
|
ES2175083T3
(es)
|
1995-03-14 |
2002-11-16 |
Praecis Pharm Inc |
Moduladores de la agregacion de amiloides.
|
|
US6303567B1
(en)
|
1995-03-14 |
2001-10-16 |
Praecis Pharmaceuticals, Inc . |
Modulators of β-amyloid peptide aggregation comprising D-amino acids
|
|
US5817626A
(en)
|
1995-03-14 |
1998-10-06 |
Praecis Pharmaceuticals Incorporated |
Modulators of beta-amyloid peptide aggregation
|
|
US5854215A
(en)
|
1995-03-14 |
1998-12-29 |
Praecis Pharmaceuticals Incorporated |
Modulators of β-amyloid peptide aggregation
|
|
US6121022A
(en)
*
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
*
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
JPH11508126A
(ja)
|
1995-05-23 |
1999-07-21 |
モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー |
多量体タンパク質
|
|
WO1996039176A1
(en)
|
1995-06-05 |
1996-12-12 |
Brigham & Women's Hospital |
USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
|
|
EP0750907B1
(en)
|
1995-06-30 |
2002-03-20 |
American Cyanamid Company |
Stable macrolide and macrolide vaccine compositions
|
|
CA2226255A1
(en)
|
1995-07-07 |
1997-01-30 |
Darwin Molecular Corporation |
Chromosome 1 gene and gene products related to alzheimer's disease
|
|
US6267958B1
(en)
*
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
CA2229043C
(en)
|
1995-08-18 |
2016-06-07 |
Morphosys Gesellschaft Fur Proteinoptimierung Mbh |
Protein/(poly)peptide libraries
|
|
US5824322A
(en)
|
1995-08-21 |
1998-10-20 |
Cytrx Corporation |
Compositions and methods for growth promotion
|
|
DE69632056T2
(de)
|
1995-09-14 |
2004-12-30 |
The Regents Of The University Of California, Oakland |
Für natives prp-sc spezifische antikörper
|
|
US5731284A
(en)
*
|
1995-09-28 |
1998-03-24 |
Amgen Inc. |
Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
|
|
US5985242A
(en)
|
1995-10-27 |
1999-11-16 |
Praecis Pharmaceuticals, Inc. |
Modulators of β-amyloid peptide aggregation comprising D-amino acids
|
|
US5750361A
(en)
|
1995-11-02 |
1998-05-12 |
The Regents Of The University Of California |
Formation and use of prion protein (PRP) complexes
|
|
EP1281718A3
(en)
|
1995-11-10 |
2005-01-19 |
ELAN CORPORATION, Plc |
Peptides which enhance transport across tissues
|
|
EP0866805A1
(en)
|
1995-12-12 |
1998-09-30 |
Karolinska Innovations AB |
PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
|
|
US5770700A
(en)
*
|
1996-01-25 |
1998-06-23 |
Genetics Institute, Inc. |
Liquid factor IX formulations
|
|
EP0883686A1
(en)
|
1996-02-26 |
1998-12-16 |
Morphosys Gesellschaft für Proteinoptimierung mbH |
Novel method for the identification of nucleic acid sequences encoding two or more interacting (poly)peptides
|
|
US6150091A
(en)
|
1996-03-06 |
2000-11-21 |
Baylor College Of Medicine |
Direct molecular diagnosis of Friedreich ataxia
|
|
US6284533B1
(en)
|
1996-05-01 |
2001-09-04 |
Avant Immunotherapeutics, Inc. |
Plasmid-based vaccine for treating atherosclerosis
|
|
EP0938506B1
(en)
|
1996-07-16 |
2003-11-05 |
Plückthun, Andreas, Prof. Dr. |
Immunoglobulin superfamily domains and fragments with increased solubility
|
|
CA2183901A1
(en)
|
1996-08-22 |
1998-02-23 |
Johanna E. Bergmann |
Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
|
|
DE69733655T2
(de)
|
1996-08-27 |
2006-04-27 |
Praecis Pharmaceuticals, Inc., Cambridge |
beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN
|
|
US6057367A
(en)
|
1996-08-30 |
2000-05-02 |
Duke University |
Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
|
|
US6797495B2
(en)
|
1996-11-05 |
2004-09-28 |
The Regents Of The University Of California |
Somatic cells with ablated PrP gene and methods of use
|
|
US6022859A
(en)
|
1996-11-15 |
2000-02-08 |
Wisconsin Alumni Research Foundation |
Inhibitors of β-amyloid toxicity
|
|
AU5508798A
(en)
|
1996-11-19 |
1998-06-10 |
Trustees Of The University Of Pennsylvania, The |
Diagnostic and therapeutic reagents for alzheimer's disease
|
|
US6962984B2
(en)
|
1996-12-05 |
2005-11-08 |
Nihon University |
IgA nephropathy-related DNA
|
|
US20030068316A1
(en)
|
1997-02-05 |
2003-04-10 |
Klein William L. |
Anti-ADDL antibodies and uses thereof
|
|
US6218506B1
(en)
|
1997-02-05 |
2001-04-17 |
Northwestern University |
Amyloid β protein (globular assembly and uses thereof)
|
|
US6277375B1
(en)
*
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US5798102A
(en)
*
|
1997-03-04 |
1998-08-25 |
Milkhaus Laboratory, Inc. |
Treatment of cardiomyopathy
|
|
US20020086847A1
(en)
|
1997-04-09 |
2002-07-04 |
Mindset Biopharmaceuticals (Usa) |
Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
|
|
US8173127B2
(en)
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
|
ATE402717T1
(de)
|
1997-04-09 |
2008-08-15 |
Intellect Neurosciences Inc |
Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
|
|
US6787319B2
(en)
|
1997-04-16 |
2004-09-07 |
American Home Products Corp. |
β-amyloid peptide-binding proteins and polynucleotides encoding the same
|
|
DE69838294T2
(de)
*
|
1997-05-20 |
2009-08-13 |
Ottawa Health Research Institute, Ottawa |
Verfahren zur Herstellung von Nukleinsäurekonstrukten
|
|
DK0999853T3
(da)
|
1997-06-13 |
2003-04-22 |
Genentech Inc |
Stabiliseret antostofformulering
|
|
AU8269898A
(en)
|
1997-06-27 |
1999-01-19 |
Regents Of The University Of California, The |
Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
|
|
IT1293511B1
(it)
|
1997-07-30 |
1999-03-01 |
Gentili Ist Spa |
Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
|
|
EP1001987B1
(en)
|
1997-08-01 |
2010-12-15 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
|
|
WO1999006587A2
(en)
|
1997-08-01 |
1999-02-11 |
Morphosys Ag |
Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
|
|
ES2500490T3
(es)
|
1997-08-29 |
2014-09-30 |
Antigenics Inc. |
Composiciones que comprenden el adyuvante QS-21 y polisorbato o ciclodextrina como excipiente
|
|
US6175057B1
(en)
*
|
1997-10-08 |
2001-01-16 |
The Regents Of The University Of California |
Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
|
|
EP0921189B1
(en)
*
|
1997-11-14 |
2005-01-12 |
Sankyo Company Limited |
Transgenic animal allergy models and methods for their use
|
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US6923964B1
(en)
*
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
|
US6750324B1
(en)
*
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
|
US6743427B1
(en)
*
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US6710226B1
(en)
*
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
PL340736A1
(en)
|
1997-12-03 |
2001-02-26 |
Fujisawa Pharmaceutical Co |
Drug in the form of soft granules and method of obtaining same
|
|
ES2253839T3
(es)
|
1997-12-03 |
2006-06-01 |
Neuralab, Ltd. |
Supresion de cambios relacionados con amiloide beta en la enfermedad de alzheimer.
|
|
FR2777015B3
(fr)
|
1998-02-23 |
2000-09-15 |
Financ De Biotechnologie |
Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
|
|
US6194551B1
(en)
*
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
*
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
|
US20050059591A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
EP1073464B1
(en)
*
|
1998-04-28 |
2004-10-06 |
Smithkline Beecham Corporation |
Monoclonal antibodies with reduced immunogenicity
|
|
NO314086B1
(no)
|
1998-05-08 |
2003-01-27 |
Gemvax As |
Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
|
|
WO1999060021A2
(en)
|
1998-05-19 |
1999-11-25 |
Yeda Research And Development Co. Ltd. |
Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
|
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
|
PT1078005E
(pt)
|
1998-05-21 |
2010-08-30 |
Univ Tennessee Res Foundation |
Processo de eleminação de amilóide usando anticorpos antiamilóide
|
|
US6727349B1
(en)
|
1998-07-23 |
2004-04-27 |
Millennium Pharmaceuticals, Inc. |
Recombinant anti-CCR2 antibodies and methods of use therefor
|
|
JP2002526419A
(ja)
|
1998-10-05 |
2002-08-20 |
ファーメクサ エイ／エス |
治療上のワクチン注射のための新規な方法
|
|
EP1150688A4
(en)
|
1998-10-19 |
2004-06-16 |
Yeda Res & Dev |
TREATING SYSTEMIC LUPUS ERYTHEMATODES BY REGULATING THE AUTOIMMUNE RESPONSE TO AUTOANTIGENS
|
|
GB2348203B
(en)
|
1998-11-04 |
2002-06-19 |
Imp College Innovations Ltd |
Solube beta-forms of prion proteins, methods of preparation and use
|
|
PT1148891E
(pt)
|
1999-01-19 |
2004-08-31 |
Upjohn Co |
Metodo para embalar uma substancia medicinal sensivel a oxidacao
|
|
CA2361124A1
(en)
|
1999-01-22 |
2000-07-27 |
Matthew John During |
Vaccine-mediated treatment of neurological disorders
|
|
EP1173480B1
(en)
|
1999-05-05 |
2008-01-16 |
Neurochem (International) Limited |
Stereoselective antifibrillogenic peptides
|
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
|
PE20010212A1
(es)
|
1999-06-01 |
2001-02-22 |
Neuralab Ltd |
Composiciones del peptido a-beta y procesos para producir las mismas
|
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
DK1409654T3
(da)
|
1999-06-16 |
2008-12-08 |
Boston Biomedical Res Inst |
Immunologisk styring af beta-amyloid-niveauer in vivo
|
|
NZ516664A
(en)
|
1999-07-15 |
2003-06-30 |
Inst Genetics Llc |
Formulations and compositions for interleukin-11
|
|
ATE445639T1
(de)
|
1999-08-04 |
2009-10-15 |
Univ Southern California |
Globularer aufbau vom amyloid-beta- protein und deren verwendungen
|
|
DE60044057D1
(de)
*
|
1999-09-03 |
2010-05-06 |
Univ Ramot |
Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung
|
|
US6294171B2
(en)
|
1999-09-14 |
2001-09-25 |
Milkhaus Laboratory, Inc. |
Methods for treating disease states comprising administration of low levels of antibodies
|
|
AU784312B2
(en)
|
1999-11-29 |
2006-03-09 |
Bellus Health (International) Limited |
Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
|
|
US20020094335A1
(en)
|
1999-11-29 |
2002-07-18 |
Robert Chalifour |
Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
|
|
CA2393763A1
(en)
|
1999-12-08 |
2001-06-14 |
Mindset Biopharmaceuticals (Usa), Inc. |
Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
|
|
US6399314B1
(en)
|
1999-12-29 |
2002-06-04 |
American Cyanamid Company |
Methods of detection of amyloidogenic proteins
|
|
CZ20022748A3
(cs)
|
2000-02-21 |
2004-03-17 |
Pharmexa A/S |
Nová metoda regulace obsahu amyloidu
|
|
EE200200444A
(et)
|
2000-02-21 |
2003-12-15 |
Pharmexa A/S |
Meetod autoloogse beeta-amüloidvaigu in vivo mahasurumiseks, amüloidogeense polüpeptiidi analoog, seda kodeeriv nukleiinhappefragment ning kasutamineimmunogeense kompositsiooni valmistamiseks
|
|
SK288711B6
(sk)
*
|
2000-02-24 |
2019-11-05 |
Univ Washington |
Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
|
|
US6992984B1
(en)
*
|
2000-03-07 |
2006-01-31 |
Lucent Technologies Inc. |
Credit-based adaptive flow control for multi-stage multi-dimensional switching architecture
|
|
CA2404237C
(en)
|
2000-04-05 |
2010-01-26 |
University Of Tennessee Research Corporation |
Methods of investigating, diagnosing, and treating amyloidosis
|
|
DE60108111T2
(de)
|
2000-05-22 |
2005-12-08 |
New York University |
Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate
|
|
EP2082749A3
(en)
|
2000-07-07 |
2010-06-30 |
Bioarctic Neuroscience AB |
Prevention and treatment of Alzheimer's disease
|
|
EP1172378A1
(en)
|
2000-07-12 |
2002-01-16 |
Richard Dr. Dodel |
Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
|
|
US20020009445A1
(en)
|
2000-07-12 |
2002-01-24 |
Yansheng Du |
Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
|
|
US20030092145A1
(en)
*
|
2000-08-24 |
2003-05-15 |
Vic Jira |
Viral vaccine composition, process, and methods of use
|
|
AU2001290638C1
(en)
|
2000-09-06 |
2009-04-30 |
Aventis Pharma S.A. |
Methods and compositions for diseases associated with amyloidosis
|
|
IT1319277B1
(it)
|
2000-10-24 |
2003-09-26 |
Chiesi Farma Spa |
Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
|
|
IL139308A0
(en)
|
2000-10-26 |
2001-11-25 |
Marikovsky Moshe |
Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
|
|
PT1346041E
(pt)
|
2000-11-27 |
2007-06-05 |
Praecis Pharm Inc |
Agentes terapêuticos e métodos para a sua utilização no tratamento de uma doença amiloidogénica.
|
|
TWI255272B
(en)
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
WO2002060920A2
(en)
|
2000-12-27 |
2002-08-08 |
Board Of Regents, University Of Texas System |
Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
|
|
WO2002059621A2
(en)
|
2001-01-24 |
2002-08-01 |
Bayer Corporation |
Regulation of transthyretin to treat obesity
|
|
DE60121729T2
(de)
|
2001-04-19 |
2007-11-29 |
Dr. Hermann Schätzl |
Prion Proteindimere für Impfungen
|
|
DE60229051D1
(de)
|
2001-04-30 |
2008-11-06 |
Lilly Co Eli |
Humanisierte antikörper
|
|
DE60230736D1
(de)
*
|
2001-04-30 |
2009-02-26 |
Lilly Co Eli |
HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
|
|
US6906169B2
(en)
|
2001-05-25 |
2005-06-14 |
United Biomedical, Inc. |
Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
|
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
|
AU2002345843A1
(en)
|
2001-06-22 |
2003-01-08 |
Panacea Pharmaceuticals, Inc. |
Compositions and methods for preventing protein aggregation in neurodegenerative diseases
|
|
US20030113316A1
(en)
|
2001-07-25 |
2003-06-19 |
Kaisheva Elizabet A. |
Stable lyophilized pharmaceutical formulation of IgG antibodies
|
|
US20030135035A1
(en)
*
|
2001-08-09 |
2003-07-17 |
Mark Shannon |
Human ZZAP1 protein
|
|
WO2003016466A2
(en)
|
2001-08-17 |
2003-02-27 |
Eli Lilly And Company |
ANTI-Aβ ANTIBODIES
|
|
US20060073149A1
(en)
|
2001-08-17 |
2006-04-06 |
Bales Kelly R |
Rapid improvement of cognition in condition related to abeta
|
|
EP1429805A4
(en)
|
2001-08-17 |
2005-09-21 |
Lilly Co Eli |
USE OF ANTIBODIES WITH HIGH AFFINITY FOR A $ G (B) PEPTIDE IN THE TREATMENT OF DISEASES AND DISEASES RELATED TO A $ G (B)
|
|
US20030082191A1
(en)
|
2001-08-29 |
2003-05-01 |
Poduslo Joseph F. |
Treatment for central nervous system disorders
|
|
US7781413B2
(en)
*
|
2001-10-31 |
2010-08-24 |
Board Of Regents, The University Of Texas System |
SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
|
|
CA2466034C
(en)
|
2001-11-08 |
2012-12-18 |
Protein Design Labs, Inc. |
Stable aqueous pharmaceutical formulations of daclizumab antibodies
|
|
EP1572894B1
(en)
|
2001-11-21 |
2016-04-13 |
New York University |
Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
|
|
WO2003051374A2
(en)
|
2001-12-17 |
2003-06-26 |
New York State Office Of Mental Health |
SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
|
|
AR038568A1
(es)
*
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
|
WO2003072036A2
(en)
|
2002-02-21 |
2003-09-04 |
Duke University |
Treatment methods using anti-cd22 antibodies
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
WO2004013172A2
(en)
|
2002-07-24 |
2004-02-12 |
Innogenetics N.V. |
Fragments of beta-amyloid as targets for vaccination against alzheimer disease
|
|
EP1545582A4
(en)
|
2002-10-01 |
2008-09-17 |
Univ Northwestern |
DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF
|
|
FR2846667B1
(fr)
|
2002-11-06 |
2004-12-31 |
Pasteur Institut |
Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
US6787129B1
(en)
*
|
2003-01-13 |
2004-09-07 |
Zenitech Llc |
Castor polyester as gloss agents in anionic systems
|
|
JP2006516639A
(ja)
|
2003-02-01 |
2006-07-06 |
ニユーララブ・リミテツド |
可溶性Ａ−βに対する抗体を生成させるための能動免疫
|
|
WO2004071408A2
(en)
|
2003-02-10 |
2004-08-26 |
Applied Molecular Evolution, Inc. |
Aβ BINDING MOLECULES
|
|
PL1610820T5
(pl)
|
2003-04-04 |
2014-01-31 |
Genentech Inc |
Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
|
|
EP1480041A1
(en)
|
2003-05-22 |
2004-11-24 |
Innogenetics N.V. |
Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
|
|
TWI374893B
(en)
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
WO2005014041A2
(en)
|
2003-07-24 |
2005-02-17 |
Novartis Ag |
Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
|
|
US20060233788A1
(en)
|
2003-09-05 |
2006-10-19 |
Heiman Mark L |
Anti-ghrelin antibodies
|
|
SG182189A1
(en)
|
2003-12-17 |
2012-07-30 |
Elan Pharma Int Ltd |
A(beta) immunogenic peptide carrier conjugates and methods of producing same
|
|
HUE026000T2
(en)
*
|
2003-12-17 |
2016-04-28 |
Wyeth Llc |
Immunogenic peptide-bearing conjugates and methods for their preparation
|
|
EA200700751A1
(ru)
*
|
2004-10-05 |
2008-06-30 |
Элан Фарма Интернэшнл Лимитед |
Способы и композиции для улучшения продуцирования рекомбинантного белка
|
|
WO2006047670A2
(en)
*
|
2004-10-26 |
2006-05-04 |
Wyeth |
Methods for assessing antibodies to neurodegenerative disease-associated antigens
|
|
US20060153772A1
(en)
*
|
2004-12-15 |
2006-07-13 |
Wyeth |
Contextual fear conditioning for predicting immunotherapeutic efficacy
|
|
CA2590337C
(en)
|
2004-12-15 |
2017-07-11 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
|
WO2006066171A1
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Amyloid βετα antibodies for use in improving cognition
|
|
WO2006066233A1
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
|
|
TW200636066A
(en)
*
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized antibodies that recognize beta amyloid peptide
|
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
MX2007009091A
(es)
|
2005-01-28 |
2008-01-11 |
Wyeth Corp |
Formulaciones de polipeptido liquidas estabilizadas.
|
|
KR101247836B1
(ko)
*
|
2005-06-17 |
2013-03-28 |
와이어쓰 엘엘씨 |
항 ａ 베타 항체의 정제 방법
|